Ovid Therapeutics Q3 EPS $(0.16) Beats $(0.19) Estimate, Sales $109.00K Beat $50.00K Estimate
Author: Benzinga Newsdesk | November 03, 2023 08:16am
Ovid Therapeutics (NASDAQ:
OVID) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 5.88 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $109.00 thousand which beat the analyst consensus estimate of $50.00 thousand by 118.00 percent. This is a 881.81 percent increase over sales of $11.10 thousand the same period last year.
Posted In: OVID